Göttingen tissue engineering enables drug screening thanks to new production methods
MBM ScienceBridge GmbH has successfully negotiated an extension of the existing license agreement between the Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (UMG) and the Göttingen-based biotech company Tissue Systems Holding GmbH on the extended commercial use of culturing methods for standardized production of human micro tissues and stem cell-based cells. The technologies are based on the scientific achievements in the field of stem cell based tissue engineering and laboratory automation of the research team led by Prof. Dr. Wolfram-Hubertus Zimmermann, Director of the Institute of Pharmacology and Toxicology at the University Medical Center of Göttingen. The extended exclusive license agreement provides for one-time payments and, in addition to sales-related license fees, an annual minimum license fee.
Nowadays, search for suitable drug candidates and risk assessments are mainly carried out using cell cultures and animal models. However, these models have limited significance for the human organism. The lack of organ physiologiology and functional maturity in standard cell cultures is a challenge that needs to be overcome. "The key to drug development are models based on tissue engineering with functional properties that are characteristic for health and disease. The platforms developed at UMG are aimed at the highest degree of functional maturation. They enable detailed impact analyses and a rational dosage strategy for early clinical studies", says Prof. Zimmermann.
Myoelectric prosthesis control with several degrees of freedom
MBM ScienceBridge GmbH successfully negotiates an exploitation agreement for a prosthesis steering control system between the University Medical Center Göttingen and the global player Otto Bock HealthCare GmbH
The prosthesis control involves a multi-functional limb movement auxiliary device and a steering method based on combined estimation regimes of multiple degrees of freedom. This allows a fluent, almost natural movement of the prosthesis. The system including sensors, analysis unit and stimulation unit are contained in the prosthesis. No surgery is required. Otto Bock receives the exclusive rights for commercial exploitation The University and their scientists receive finantial payments in return.
New perspectives in the biosynthesis of lipids in plants
The MBM Science Bridge GmbH successfully negotiates agreement between Georg-August-University Göttingen and Bayer CropScience to optimize biosynthesis of lipids in plants.
Scientists at the Albrecht-von-Haller-Institute of Plant Sciences of the Georg-August-University of Göttingen developed an innovative method for the biosynthesis of lipids in plants. The plant lipids can be used as a renewable source of chemical compounds, in particular for the lubricants market. The technology transfer organisation of the Georg-August-University of Göttingen successfully negotiated an agreement with the international company Bayer CropScience for this invention.
Swiss pharmaceutical company licensed Göttingen cell lines
Göttingen technology transfer organization MBM ScienceBridge GmbH succeeded in closing a license deal for antibody-producing cell lines with an international company - the Swiss pharmaceutical company F. Hoffmann-La Roche Ltd. The cell lines derived from the Department of Immunology of the Göttingen Universitätsmedizin is a further example of successful commercialization of research materials from antibody research.
The scientists led by Professor Martin Oppermann of the Department of Immunology, Georg-August-University Göttingen mainly work on the physiological and pathological functions of the complement system, an integral part of the body's immune system and have developed a variety of monoclonal antibodies and cell lines against factors of complement system in the last years, which are used for research purposes, but also find applications in the development of diagnostic tests and therapeutic solutions.